$BUD, $CMCSA, $JAZZ, $KBH, $KMI, $NLTX
Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.
Below is the list for Friday, 13 March, as follows:
Anheuser-Busch InBev S.A./N.V. (NYSE:BUD) was raised to Outperform from Sector Perform at RBC Capital Markets, with the firm citing excess share price weakness and its aggressive debt reduction efforts
Comcast Corp. (NASDAQ:CMCSA) was maintained as Overweight at KeyBanc Capital Markets, but the target price was lowered to 46 from 50 in the call.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was raised to Outperform from Market Perform but its target price was lowered to 166 from 175 at Bernstein.
KB Home (NYSE:KBH) was raised to Buy from Neutral at BofA Securities, but the firm lowered its price target to 36 from 44.
Kinder Morgan Inc. (NYSE:KMI) was raised to Outperform from Market Perform at Raymond James.
Neoleukin Therapeutics Inc. (NASDAQ:NLTX) was started with a Buy rating and a 20 target price at Canaccord Genuity
Have a terrific weekend
Latest posts by HEFFX (see all)
- Xiaomi Follows Huawei Onto The USA Blacklist - January 15, 2021
- BlackBerry Huawei Patent Deal - January 15, 2021
- Data Protection Regulators in any European Country can Bring Privacy Complaints Against Facebook - January 15, 2021